• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960
June 17, 2021


BRAXIA SCIENTIFIC TO PRESENT AT THE PSYCHEDELICS IN PSYCHIATRY AND BEYOND VIRTUAL CONFERENCE HOSTED BY H.C. WAINWRIGHT & CO. ON JUNE 17, 2021 TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Psychedelics in Psychiatry and Beyond Virtual Conference, hosted by H.C. Wainwright & Co. on June 17, 2021. Braxia’s CEO, Dr. Roger McIntyre will present and participate in a panel discussion, “Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry.”   Dr. McIntyre will also be available to host virtual one-on-one meetings with institutional investors registered with H.C. Wainwright and Co. For additional information on the conference please visit: https://hcwevents.com/psychedelics/ About Braxia Scientific Corp. Braxia Scientific is a...